Oncology

Recent increases in the number of therapies indicated for a given oncology subtype has resulted in heightened utilization management stringency.

Most read articles of the week on Specialty Pharmacy Times.

Diabetes and other conditions are also influenced by a person’s height.

Gilotrif shows significant reduction in the risk of adenocarcinoma progression.

Inherited genetic variations leave acute lymphoblastic leukemia patients sensitive to drugs and at risk for toxicity.

Enhanced tumor analysis can help identify individual therapeutic cancer strategies.

Issues with learning and paying attention associated with intensive chemotherapy for leukemia.

Durvalumab and tremelimumab demonstrated antitumor activity in patients with non-small cell lung cancer regardless of PD-L1 status.

Durvalumab and tremelimumab demonstrated antitumor activity in patients with non-small cell lung cancer regardless of PD-L1 status.

Numerous canine breeds develop cancers such as breast cancer and melanoma that have genetic similarities with the human equivalent disease.

Research could lead to the development of new cancer treatments.

Top news of the week in oncology drug development.

Gilotrif shows significant reduction in the risk of adenocarcinoma progression.

Cancer treatment advances are now moving to the clinic with great promise, just as precision therapy and immunotherapy are transforming cancer therapy itself.

Investigators seek to stop women's cancers before it starts to form.

Nearly 40% of US employees have no access to paid sick leave.

Study assessed chemotherapy use in patients with chronic myelogenous leukemia (CML) to determine how use of CML-specific tests impacted drug selection and modification.

Trametinib and fluvastatin combination could block non-small cell lung cancer pathway activity.

New method penetrates tissue and kills the cancerous cells deep inside tumors.

The second article in a two-part series examines oncology drug approvals and late-breaking FDA actions.

Connecticut man achieves remission via Revlimid therapy while bolstered by the love of his wife and children.

Researchers find the amplification and mutation of human epidermal growth factor receptor 2 should be treated separately.

Blincyto treats adult patients with Philadelphia chromosome-negative relapsed or refractory B-cell precursor ALL.

Blincyto treats adult patients with Philadelphia chromosome-negative relapsed or refractory B-cell precursor ALL.

Emend found to provide a greater delay in nausea and vomiting from cancer treatment than other medicines.

Emend found to provide a greater delay in nausea and vomiting from cancer treatment than other medicines.

Testimony from public speakers at FDA advisory committee meetings under increased scrutiny.

Annual per patient cost for pancreatic therapies and medications found to create significant financial burden.

Early detection is key in reducing the risk of heart failure in patients with cancer.

Testimony from public speakers at FDA advisory committee meetings under increased scrutiny.